WO2024157085 - METHODS OF TREATING NEUROLOGICAL DISORDERS WITH ANTI-ABETA ANTIBODIES
National phase entry is expected:
Publication Number
WO/2024/157085
Publication Date
02.08.2024
International Application No.
PCT/IB2024/000067
International Filing Date
26.01.2024
Title **
[English]
METHODS OF TREATING NEUROLOGICAL DISORDERS WITH ANTI-ABETA ANTIBODIES
[French]
PROCÉDÉS DE TRAITEMENT DE TROUBLES NEUROLOGIQUES AVEC DES ANTICORPS ANTI-ABÊTA
Applicants **
OTHAIR PROTHENA LIMITED
Inventors
CAMPBELL, Brian, Michael
SWANSON, Chad, James
ZAGO, Wagner
Priority Data
63/481,631
26.01.2023
US
63/597,868
10.11.2023
US
63/597,861
10.11.2023
US
63/618,045
05.01.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7409 | |
| EPO | Filing, Examination, Granting | 174254 | |
| Japan | Filing, Examination, Granting | 5133 | |
| South Korea | Filing, Examination, Granting | 11118 | |
| USA | Filing, Examination, Granting | 46090 |
Total:
244,004
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.[French]
L'invention concerne des anticorps qui se lient au peptide bêta-amyloïde humain, des procédés de détection, de mesure et de traitement de troubles amyloïdogènes avec lesdits anticorps, des compositions pharmaceutiques comprenant les anticorps et des procédés de fabrication.